KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Boston Scientific (BSX) Other Accumulated Expenses (2016 - 2025)

Boston Scientific's Other Accumulated Expenses history spans 17 years, with the latest figure at $152.0 million for Q3 2025.

  • For Q3 2025, Other Accumulated Expenses fell 78.32% year-over-year to $152.0 million; the TTM value through Sep 2025 reached $152.0 million, down 78.32%, while the annual FY2023 figure was $814.0 million, 6.96% up from the prior year.
  • Other Accumulated Expenses for Q3 2025 was $152.0 million at Boston Scientific, down from $701.0 million in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $814.0 million in Q4 2023 and bottomed at $152.0 million in Q3 2025.
  • The 5-year median for Other Accumulated Expenses is $661.0 million (2021), against an average of $557.7 million.
  • The largest annual shift saw Other Accumulated Expenses skyrocketed 188.26% in 2022 before it crashed 78.32% in 2025.
  • A 5-year view of Other Accumulated Expenses shows it stood at $264.0 million in 2021, then surged by 188.26% to $761.0 million in 2022, then increased by 6.96% to $814.0 million in 2023, then dropped by 13.88% to $701.0 million in 2024, then plummeted by 78.32% to $152.0 million in 2025.
  • Per Business Quant, the three most recent readings for BSX's Other Accumulated Expenses are $152.0 million (Q3 2025), $701.0 million (Q3 2024), and $770.0 million (Q2 2024).